FI20075278A0 - Nya fullständigt humana anti-VAP-1 monoklonala antikroppar - Google Patents

Nya fullständigt humana anti-VAP-1 monoklonala antikroppar

Info

Publication number
FI20075278A0
FI20075278A0 FI20075278A FI20075278A FI20075278A0 FI 20075278 A0 FI20075278 A0 FI 20075278A0 FI 20075278 A FI20075278 A FI 20075278A FI 20075278 A FI20075278 A FI 20075278A FI 20075278 A0 FI20075278 A0 FI 20075278A0
Authority
FI
Finland
Prior art keywords
vap
monoclonal antibodies
human anti
completely human
novel completely
Prior art date
Application number
FI20075278A
Other languages
English (en)
Finnish (fi)
Inventor
David John Smith
Petri Vainio
Jari Mikkola
Paeivi Vuorio
Jani Vainio
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Priority to FI20075278A priority Critical patent/FI20075278A0/sv
Publication of FI20075278A0 publication Critical patent/FI20075278A0/sv
Priority to SI200831444T priority patent/SI2164872T1/sl
Priority to PCT/FI2008/050199 priority patent/WO2008129124A1/en
Priority to PL13190488T priority patent/PL2692737T3/pl
Priority to EP08736848.6A priority patent/EP2164872B1/en
Priority to UAA200910613A priority patent/UA97516C2/ru
Priority to DK08736848.6T priority patent/DK2164872T3/en
Priority to CA2683079A priority patent/CA2683079C/en
Priority to RU2009142808/10A priority patent/RU2459832C2/ru
Priority to JP2010503537A priority patent/JP5728225B2/ja
Priority to LTEP13190488.0T priority patent/LT2692737T/lt
Priority to PL08736848T priority patent/PL2164872T3/pl
Priority to AU2008240560A priority patent/AU2008240560B2/en
Priority to CN2008800209043A priority patent/CN101679523B/zh
Priority to CA2962519A priority patent/CA2962519C/en
Priority to ES13190488.0T priority patent/ES2690307T3/es
Priority to EP13190488.0A priority patent/EP2692737B1/en
Priority to KR1020097021869A priority patent/KR101352416B1/ko
Priority to DK13190488.0T priority patent/DK2692737T3/en
Priority to SI200832000T priority patent/SI2692737T1/sl
Priority to PT87368486T priority patent/PT2164872E/pt
Priority to PT13190488T priority patent/PT2692737T/pt
Priority to CA3059600A priority patent/CA3059600C/en
Priority to ES08736848.6T priority patent/ES2540566T3/es
Priority to CA3059580A priority patent/CA3059580C/en
Priority to NZ580194A priority patent/NZ580194A/en
Priority to CA3059571A priority patent/CA3059571C/en
Priority to RS20150427A priority patent/RS54066B1/en
Priority to HUE13190488A priority patent/HUE041656T2/hu
Priority to US12/081,707 priority patent/US7897149B2/en
Priority to ZA200907220A priority patent/ZA200907220B/xx
Priority to IL201601A priority patent/IL201601A/en
Priority to HK10107584.5A priority patent/HK1141039A1/xx
Priority to US12/940,476 priority patent/US8142783B2/en
Priority to HRP20150615TT priority patent/HRP20150615T1/hr
Priority to CY20151100533T priority patent/CY1116413T1/el
Priority to CY181101032T priority patent/CY1121132T1/el
Priority to HRP20181616TT priority patent/HRP20181616T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
FI20075278A 2007-04-20 2007-04-20 Nya fullständigt humana anti-VAP-1 monoklonala antikroppar FI20075278A0 (sv)

Priority Applications (38)

Application Number Priority Date Filing Date Title
FI20075278A FI20075278A0 (sv) 2007-04-20 2007-04-20 Nya fullständigt humana anti-VAP-1 monoklonala antikroppar
PT87368486T PT2164872E (pt) 2007-04-20 2008-04-17 Anticorpos monoclonais anti-vap-1 totalmente humanos
DK13190488.0T DK2692737T3 (en) 2007-04-20 2008-04-17 Fully human anti-VAP-1 monoclonal antibodies
HUE13190488A HUE041656T2 (hu) 2007-04-20 2008-04-17 Teljesen humán anti-VAP-1 monoklonális antitestek
PL13190488T PL2692737T3 (pl) 2007-04-20 2008-04-17 W pełni ludzkie przeciwciała monoklonalne anty-vap-1
SI200832000T SI2692737T1 (sl) 2007-04-20 2008-04-17 V celoti humana proti -VAP-1 monoklonalna protitelesa
UAA200910613A UA97516C2 (ru) 2007-04-20 2008-04-17 Полностью человеческое моноклональное антитело против vap-1
DK08736848.6T DK2164872T3 (en) 2007-04-20 2008-04-17 COMPLETE human anti-VAP-1 MONOCLONAL ANTIBODIES
CA2683079A CA2683079C (en) 2007-04-20 2008-04-17 Novel fully human anti-vap-1 monoclonal antibodies
RU2009142808/10A RU2459832C2 (ru) 2007-04-20 2008-04-17 Новые полностью человеческие моноклональные антитела против vap-1
JP2010503537A JP5728225B2 (ja) 2007-04-20 2008-04-17 完全ヒト抗ｖａｐ−１抗体、ｖａｐ−１結合断片、核酸分子、発現ベクター、宿主細胞、及び、薬学的組成物
LTEP13190488.0T LT2692737T (lt) 2007-04-20 2008-04-17 Pilnai žmogaus anti-vap-1 monokloniniai antikūnai
PL08736848T PL2164872T3 (pl) 2007-04-20 2008-04-17 W pełni ludzkie przeciwciała monoklonalne anty-vap-1
AU2008240560A AU2008240560B2 (en) 2007-04-20 2008-04-17 Novel fully human anti-VAP-1 monoclonal antibodies
CN2008800209043A CN101679523B (zh) 2007-04-20 2008-04-17 全人源抗vap-1单克隆抗体
CA2962519A CA2962519C (en) 2007-04-20 2008-04-17 Novel fully human anti-vap-1 monoclonal antibodies
ES13190488.0T ES2690307T3 (es) 2007-04-20 2008-04-17 Anticuerpos monoclonales anti-VAP-1 completamente humanos
PCT/FI2008/050199 WO2008129124A1 (en) 2007-04-20 2008-04-17 Novel fully human anti-vap-1 monoclonal antibodies
KR1020097021869A KR101352416B1 (ko) 2007-04-20 2008-04-17 신규의 완전한 사람형 항-ｖａｐ-1 모노클로날 항체
SI200831444T SI2164872T1 (sl) 2007-04-20 2008-04-17 V celoti humana proti -VAP-1 monoklonalna protitelesa
EP08736848.6A EP2164872B1 (en) 2007-04-20 2008-04-17 Fully human anti-vap-1 monoclonal antibodies
EP13190488.0A EP2692737B1 (en) 2007-04-20 2008-04-17 Fully human anti-VAP-1 monoclonal antibodies
CA3059600A CA3059600C (en) 2007-04-20 2008-04-17 Novel fully human anti-vap-1 monoclonal antibodies
PT13190488T PT2692737T (pt) 2007-04-20 2008-04-17 Anticorpos monoclonais anti-vap-1 totalmente humanos
ES08736848.6T ES2540566T3 (es) 2007-04-20 2008-04-17 Anticuerpos monoclonales anti-VAP-1 completamente humanos
CA3059580A CA3059580C (en) 2007-04-20 2008-04-17 Novel fully human anti-vap-1 monoclonal antibodies
NZ580194A NZ580194A (en) 2007-04-20 2008-04-17 Novel fully human anti-vap-1 monoclonal antibodies
CA3059571A CA3059571C (en) 2007-04-20 2008-04-17 Novel fully human anti-vap-1 monoclonal antibodies
RS20150427A RS54066B1 (en) 2007-04-20 2008-04-17 COMPLETELY HUMAN ANTI-VAP-1 MONOCLONAL ANTIBODIES
US12/081,707 US7897149B2 (en) 2007-04-20 2008-04-18 Fully human anti-VAP-1 monoclonal antibodies
ZA200907220A ZA200907220B (en) 2007-04-20 2009-10-15 Novel fully human anti-VAP-1 monoclonal antibodies
IL201601A IL201601A (en) 2007-04-20 2009-10-18 Human monoclonal antibodies to vap-1
HK10107584.5A HK1141039A1 (en) 2007-04-20 2010-08-09 Fully human anti-vap-1 monoclonal antibodies vap-1
US12/940,476 US8142783B2 (en) 2007-04-20 2010-11-05 Methods of treating an inflammatory condition involving VAP-1-mediated adhesion with VAP-1-specific antibodies
HRP20150615TT HRP20150615T1 (hr) 2007-04-20 2015-06-08 Potpuno ljudska anti-vap-1 monoklonska protutijela
CY20151100533T CY1116413T1 (el) 2007-04-20 2015-06-23 Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1
CY181101032T CY1121132T1 (el) 2007-04-20 2018-10-05 ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
HRP20181616TT HRP20181616T1 (hr) 2007-04-20 2018-10-05 Potpuno ljudska anti-vap-1 monoklonska antitijela

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20075278A FI20075278A0 (sv) 2007-04-20 2007-04-20 Nya fullständigt humana anti-VAP-1 monoklonala antikroppar

Publications (1)

Publication Number Publication Date
FI20075278A0 true FI20075278A0 (sv) 2007-04-20

Family

ID=38009931

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20075278A FI20075278A0 (sv) 2007-04-20 2007-04-20 Nya fullständigt humana anti-VAP-1 monoklonala antikroppar

Country Status (25)

Country Link
US (2) US7897149B2 (sv)
EP (2) EP2164872B1 (sv)
JP (1) JP5728225B2 (sv)
KR (1) KR101352416B1 (sv)
CN (1) CN101679523B (sv)
AU (1) AU2008240560B2 (sv)
CA (5) CA3059571C (sv)
CY (2) CY1116413T1 (sv)
DK (2) DK2164872T3 (sv)
ES (2) ES2690307T3 (sv)
FI (1) FI20075278A0 (sv)
HK (1) HK1141039A1 (sv)
HR (2) HRP20150615T1 (sv)
HU (1) HUE041656T2 (sv)
IL (1) IL201601A (sv)
LT (1) LT2692737T (sv)
NZ (1) NZ580194A (sv)
PL (2) PL2692737T3 (sv)
PT (2) PT2164872E (sv)
RS (1) RS54066B1 (sv)
RU (1) RU2459832C2 (sv)
SI (2) SI2164872T1 (sv)
UA (1) UA97516C2 (sv)
WO (1) WO2008129124A1 (sv)
ZA (1) ZA200907220B (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20075278A0 (sv) * 2007-04-20 2007-04-20 Biotie Therapies Corp Nya fullständigt humana anti-VAP-1 monoklonala antikroppar
TWI428142B (zh) * 2009-05-08 2014-03-01 Genentech Inc 人類化之抗－ｅｇｆｌ７抗體及其使用方法
UA112154C2 (uk) * 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
TWI594764B (zh) * 2010-04-12 2017-08-11 生化治療公司 治療用途
ES2702246T3 (es) * 2012-03-26 2019-02-28 Sanofi Sa Formulaciones de agente de unión IgG4 estables
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
DK3729958T3 (da) * 2013-03-15 2023-08-07 Mayo Found Medical Education & Res Identificering og overvågning af monoklonale immunoglobuliner ved hjælp af molekylmasse
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
JP6759104B2 (ja) 2014-04-04 2020-09-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 精密分子質量を用いた免疫グロブリンのアイソタイピング
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
EP3175242A4 (en) 2014-07-29 2017-12-27 Mayo Foundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
CN104628853B (zh) * 2015-02-06 2017-10-10 中国人民解放军南京军区军事医学研究所 人源抗炭疽保护性抗原PA的抗体IgG及其应用
US11209439B2 (en) 2015-09-24 2021-12-28 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
CA3007768A1 (en) 2015-12-07 2017-06-15 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
US11161902B2 (en) 2016-05-09 2021-11-02 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Tissue-specific exosomes as biomarkers
CN109863395B (zh) 2016-09-07 2023-05-23 梅约医学教育与研究基金会 分子量法鉴定和监测裂解免疫球蛋白
AU2018261947A1 (en) 2017-05-05 2019-11-07 Vaccinex, Inc. Human anti-semaphorin 4D antibody
EP3681528A4 (en) 2017-09-13 2021-07-21 Mayo Foundation for Medical Education and Research IDENTIFICATION AND MONITORING OF THE APOPTOSIS INHIBITOR OF MACROPHAGES
KR20200067195A (ko) * 2017-10-18 2020-06-11 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항체 치료제
CN111537740B (zh) * 2020-05-22 2021-11-23 长春生物制品研究所有限责任公司 一种森林脑炎病毒IgM抗体检测试剂盒及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5580780A (en) * 1992-06-09 1996-12-03 Jalkanen; Sirpa Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies
NZ299958A (en) * 1992-06-09 2000-07-28 Marko Salmi Antagonising endothelial vascular adhesion protein-1 (VAP-1) mediated binding of endothelial cells to lymphocytes using anti-VAP-1-antibodiess
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CN1269829A (zh) * 1997-05-23 2000-10-11 拜奥泰治疗有限公司 有胺氧化酶活性的血管粘着蛋白－1
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU2003222185A1 (en) * 2002-04-01 2003-10-20 Utah Ventures Ii, L.P. Tissue-specific endothelial membrane proteins
FI20020807A0 (sv) * 2002-04-29 2002-04-29 Biotie Therapies Oyj Nya humaniserade anti-VAP-1 monoklonala antikroppar
FI20075278A0 (sv) * 2007-04-20 2007-04-20 Biotie Therapies Corp Nya fullständigt humana anti-VAP-1 monoklonala antikroppar

Also Published As

Publication number Publication date
EP2692737B1 (en) 2018-07-25
CA3059571C (en) 2020-06-30
NZ580194A (en) 2011-09-30
CA3059580C (en) 2020-06-30
DK2164872T3 (en) 2015-06-29
DK2692737T3 (en) 2018-10-29
ES2540566T3 (es) 2015-07-10
KR20100021562A (ko) 2010-02-25
RU2009142808A (ru) 2011-05-27
IL201601A0 (en) 2010-05-31
EP2164872B1 (en) 2015-05-27
CA3059600C (en) 2020-06-30
UA97516C2 (ru) 2012-02-27
PT2164872E (pt) 2015-07-30
US7897149B2 (en) 2011-03-01
PT2692737T (pt) 2018-10-25
EP2164872A1 (en) 2010-03-24
PL2164872T3 (pl) 2015-08-31
LT2692737T (lt) 2018-10-25
CA2962519A1 (en) 2008-10-30
EP2164872A4 (en) 2011-01-12
KR101352416B1 (ko) 2014-01-17
US8142783B2 (en) 2012-03-27
CN101679523B (zh) 2013-11-06
PL2692737T3 (pl) 2019-07-31
CA2683079A1 (en) 2008-10-30
CA2683079C (en) 2017-04-11
ES2690307T3 (es) 2018-11-20
SI2692737T1 (sl) 2019-04-30
AU2008240560B2 (en) 2012-05-17
CY1116413T1 (el) 2017-02-08
CA3059600A1 (en) 2008-10-30
ZA200907220B (en) 2010-07-28
HUE041656T2 (hu) 2019-05-28
RS54066B1 (en) 2015-10-30
SI2164872T1 (sl) 2015-07-31
IL201601A (en) 2015-06-30
HK1141039A1 (en) 2010-10-29
HRP20181616T1 (hr) 2018-12-14
CA3059580A1 (en) 2008-10-30
RU2459832C2 (ru) 2012-08-27
US20110117021A1 (en) 2011-05-19
CA2962519C (en) 2019-12-31
JP2010524449A (ja) 2010-07-22
CA3059571A1 (en) 2008-10-30
AU2008240560A1 (en) 2008-10-30
JP5728225B2 (ja) 2015-06-03
EP2692737A1 (en) 2014-02-05
CY1121132T1 (el) 2019-12-11
HRP20150615T1 (hr) 2015-07-03
WO2008129124A1 (en) 2008-10-30
US20090081126A1 (en) 2009-03-26
CN101679523A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
FI20075278A0 (sv) Nya fullständigt humana anti-VAP-1 monoklonala antikroppar
LTC2379594I2 (lt) Žmogaus CGRP receptorių rišantys antikūnai
DK2131860T3 (da) Anti-sclerostin-antistoffer
SMT201700083B (it) Anticorpi monoclonali
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0809677A2 (pt) Anticorpos anti-ige
NO344963B1 (no) Humanisert antistoff
DK2066695T3 (da) Anti-myostatin-antistoffer
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
BRPI0819165A2 (pt) Anticorpos anti-vegf
BRPI0923359A2 (pt) Anticorpos anti-igf
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0817273A2 (pt) Região constante de anticorpo modificada
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
BRPI0907237A2 (pt) Anticorpo anti-cldn6
ATE483732T1 (de) Madcam-antikörper
DK2292663T3 (da) Antagonistiske human-let-specifikke, humane monoklonale antistoffer
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
BRPI0815567A2 (pt) Anticorpos híbridos antialfa v-integrina projetados
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
BRPI0817427A2 (pt) Anticorpo anti-bst2